Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verra Mobility (VRRM) Asset Writedowns and Impairment (2018 - 2025)

Verra Mobility (VRRM) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$18.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 121.46% to -$18.4 million in Q4 2025 year-over-year; TTM through Sep 2025 was $104.0 million, a 704.8% increase, with the full-year FY2024 number at $97.1 million, up 972.19% from a year prior.
  • Asset Writedowns and Impairment was -$18.4 million for Q4 2025 at Verra Mobility, down from $4.5 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $85.7 million in Q4 2024 to a low of -$18.4 million in Q4 2025.
  • A 5-year average of $7.7 million and a median of $3.3 million in 2023 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 5606.26% in 2024, then crashed 121.46% in 2025.
  • Verra Mobility's Asset Writedowns and Impairment stood at $2.9 million in 2021, then increased by 22.04% to $3.5 million in 2022, then plummeted by 57.18% to $1.5 million in 2023, then surged by 5606.26% to $85.7 million in 2024, then plummeted by 121.46% to -$18.4 million in 2025.
  • Per Business Quant, the three most recent readings for VRRM's Asset Writedowns and Impairment are -$18.4 million (Q4 2025), $4.5 million (Q3 2025), and $5.7 million (Q2 2025).